FORT WORTH, Texas, Dec. 11 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it is exploring a potential acquisition of BioPharma Management Technologies, Inc., a company that has recently launched the development of topical pain management products. "While we have been focusing this year on expanding market penetration of our CellerateRx(R) products, we also have been working to expand our current product portfolio. We believe that the science behind BioPharma's product development shows potential and creates market synergies with our current products," says Scott Haire, Wound Management Technologies' CEO. "We believe that BioPharma's products will provide a broad application across several medical specialities. We are not aware of any currently available products in the market that provide the benefits we expect BioPharma's unique formulation to deliver."
BioPharma is developing a topical pain management product targeting the growing pain management market place. "Based on our research, we believe that this product will provide a broad application across several medical specialities while supplying a good safety profile, expanded dosing range and flexibility, and should create and maintain a moist environment conducive to drug absorption and reduction of irritation at the application site. All year we have focused on Cellerate as a one-of-a-kind product and adding an additional company and product mix should make us a leader in the wound industry and related healthcare markets," states Scott Haire, CEO of Wound Management Technologies. "Also this should significantly increase our revenues in 2010 in all areas of wound care."
CellerateRx(R) is exclusively distributed by Wound Care Innovations, a
subsidiary of Wound Management Technologies. It is a one-of-a-kind, patented,
advanced wound care collagen product and is FDA cleared for acute and ch
'/>"/>
| SOURCE Wound Management Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved |